Enb Therapeutics

Small molecule inhibitors targeting a novel pathway to treat malignant melanoma

placeNew York City, New York, United States calendar_todayFounded 2015 groups8 employees language enbpharma.com

Innovation

7 patent families (2 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 1,095 times.

YearFilings
20171
20181
20193
20205
20214
20223
20232
20242
20251
20261

Investor mix

7 investors on record; lead investors include Remiges Ventures.

Investor typeCountShare
Venture capital571%
Accelerator & incubator114%
Other / undisclosed114%
Coming soon